The NAFLD Fibrosis Score is a widely used, non-invasive tool that helps clinicians assess the risk of advanced liver scarring in patients with non-alcoholic fatty liver disease (NAFLD), now also termed metabolic dysfunction-associated steatotic liver disease (MASLD). Using six routine clinical and laboratory parameters—including age, BMI, diabetes status, platelet count, albumin, and AST/ALT ratio—the score stratifies patients into low, intermediate, or high risk categories without requiring a liver biopsy. This practical scoring system plays a key role in UK clinical pathways, guiding decisions on monitoring, further testing, and specialist referral to ensure timely management of liver fibrosis.
Summary: The NAFLD Fibrosis Score is a validated, non-invasive clinical tool that uses six routine parameters (age, BMI, diabetes status, platelet count, albumin, and AST/ALT ratio) to assess the likelihood of advanced liver fibrosis in patients with non-alcoholic fatty liver disease.
- The score stratifies patients into low risk (score <-1.455), intermediate risk (-1.455 to 0.676), or high risk (>0.676) categories for advanced liver fibrosis.
- NICE guidance (NG49) recommends the Enhanced Liver Fibrosis (ELF) test as the preferred first-line assessment, though many UK pathways use the NAFLD Fibrosis Score for initial triage.
- Intermediate-risk scores require additional testing such as the ELF test or transient elastography (FibroScan) to clarify fibrosis status.
- High-risk scores warrant referral to specialist hepatology services for comprehensive assessment and monitoring for cirrhosis complications.
- The score is validated for adults only and may overestimate fibrosis risk in patients aged 65 years or older, requiring age-adjusted interpretation.
- Lifestyle modification—particularly weight loss of 7–10% and increased physical activity—remains the cornerstone of NAFLD management, as no medications are currently licensed for NAFLD treatment in the UK.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
What Is the NAFLD Fibrosis Score?
The NAFLD Fibrosis Score is a validated, non-invasive clinical tool used to assess the likelihood of advanced liver fibrosis (scarring) in patients with non-alcoholic fatty liver disease (NAFLD). Also known as metabolic dysfunction-associated steatotic liver disease (MASLD) in recent literature, this condition affects a significant proportion of UK adults. The scoring system helps clinicians stratify patients into low, intermediate, or high risk categories for significant fibrosis without requiring an immediate liver biopsy.
The score is calculated using six readily available clinical and laboratory parameters:
-
Age (years)
-
Body mass index (BMI) in kg/m²
-
Presence of impaired fasting glucose or diabetes mellitus
-
Platelet count (×10⁹/L)
-
Serum albumin (g/L)
-
AST/ALT ratio (aspartate aminotransferase to alanine aminotransferase)
These variables are entered into a mathematical formula that generates a numerical score, typically ranging from approximately -1.5 to +3.5. The score's strength lies in its accessibility—it requires only routine blood tests and basic clinical information, making it practical for use in primary and secondary care settings across the NHS.
The NAFLD Fibrosis Score is widely used in UK clinical pathways, often as an initial triage tool. NICE guidance (NG49) recommends the Enhanced Liver Fibrosis (ELF) test as the preferred first-line assessment for advanced fibrosis in adults with NAFLD. However, many UK pathways, including those from the British Society of Gastroenterology (BSG) guidance on abnormal liver blood tests, use the NAFLD Fibrosis Score or FIB-4 index for initial risk stratification, with ELF or transient elastography as second-line tests. The score has been extensively validated in diverse populations and demonstrates good negative predictive value, meaning it is particularly reliable at ruling out advanced fibrosis in low-risk individuals.
Important limitations: The NAFLD Fibrosis Score is validated for adults only and should not be used in children, pregnant women, or those with acute hepatitis. In people aged 65 years or older, age-adjusted thresholds or alternative testing strategies may be more appropriate, as standard cut-offs can overestimate fibrosis risk in this age group. Always discuss your results with your healthcare team, who will interpret the score within your broader clinical context.
Interpreting Your NAFLD Fibrosis Score Results
Understanding your NAFLD Fibrosis Score result is essential for determining the appropriate next steps in your care pathway. The score divides patients into three distinct risk categories, each with different clinical implications and management recommendations.
Low risk (score <-1.455): A score below -1.455 suggests a low probability of advanced fibrosis (F3-F4 stage). Patients in this category typically have a negative predictive value exceeding 90%, meaning advanced scarring is highly unlikely. These individuals can usually be managed in primary care with lifestyle modification advice, regular monitoring of liver function tests, and cardiovascular risk assessment. Repeat non-invasive assessment is generally recommended every 2–3 years, or sooner if clinical circumstances change significantly. (NICE NG49 specifies 3-year retesting intervals for the ELF test; your local pathway will determine the appropriate interval for NAFLD Fibrosis Score monitoring.)
Intermediate risk (score -1.455 to 0.676): Scores falling within this range indicate uncertainty regarding fibrosis status. Approximately 25–30% of NAFLD patients fall into this indeterminate zone. For these individuals, additional non-invasive testing is typically required to clarify their fibrosis risk. In line with NICE NG49, the Enhanced Liver Fibrosis (ELF) test is the preferred next step in adults with NAFLD. Alternatively, transient elastography (FibroScan®) may be used, depending on local availability and clinical context. Your GP or specialist will arrange the most appropriate second-line test for you.
High risk (score >0.676): A score above 0.676 indicates a high probability of advanced fibrosis, with positive predictive values ranging from 60–80% depending on the population studied. Patients in this category should be referred to specialist hepatology services for comprehensive assessment. This may include further imaging, consideration of liver biopsy if clinically indicated, and discussion of participation in clinical trials where appropriate. These individuals require closer monitoring for complications of cirrhosis. If cirrhosis is confirmed, hepatocellular carcinoma (HCC) surveillance with ultrasound every 6 months (with or without alpha-fetoprotein testing, depending on local protocols) is recommended in line with BSG and British Association for the Study of the Liver (BASL) guidance.
Age-adjusted interpretation: If you are aged 65 years or older, standard NAFLD Fibrosis Score cut-offs may overestimate your fibrosis risk. Your healthcare team may use age-adjusted thresholds or recommend alternative testing strategies to ensure accurate assessment.
When Further Testing May Be Needed
Whilst the NAFLD Fibrosis Score provides valuable risk stratification, several clinical scenarios warrant additional investigation or specialist input, regardless of the initial score. Recognising these situations ensures appropriate escalation of care and prevents delayed diagnosis of significant liver disease.
Indeterminate scores represent the most common indication for further testing. When your score falls in the intermediate range (-1.455 to 0.676), your GP or hepatologist will typically arrange a second-line non-invasive test. In line with NICE NG49, the Enhanced Liver Fibrosis (ELF) test is the preferred option in adults with NAFLD. The ELF test measures three serum markers (hyaluronic acid, procollagen III N-terminal peptide, and tissue inhibitor of metalloproteinase 1) and provides additional discrimination. Alternatively, transient elastography (FibroScan®) uses ultrasound-based technology to measure liver stiffness, which correlates with fibrosis stage. Many UK pathways, including BSG guidance on abnormal liver blood tests, recommend a sequential approach: initial triage with NAFLD Fibrosis Score or FIB-4, followed by ELF or elastography to refine risk assessment.
Clinical red flags that should prompt specialist referral or urgent assessment include:
-
Urgent same-day assessment for jaundice, suspected decompensated liver disease (ascites, confusion/encephalopathy, gastrointestinal bleeding), or sepsis
-
Suspected cancer (2-week-wait referral) for focal liver lesions on imaging or other features suggestive of hepatocellular carcinoma (see NICE NG12)
-
Persistent elevation of liver enzymes (ALT persistently >2× upper limit of normal) warrants timely specialist referral, though not necessarily urgent unless accompanied by other concerning features
-
Thrombocytopenia (platelet count <150 ×10⁹/L), which may suggest portal hypertension, particularly if accompanied by splenomegaly or other signs of chronic liver disease
-
Splenomegaly detected on examination or imaging
-
Abnormal liver imaging suggesting cirrhosis or structural liver disease
Discordant results between the NAFLD Fibrosis Score and clinical impression also warrant further investigation. For example, a low score in a patient with clinical features of chronic liver disease (spider naevi, palmar erythema, hepatomegaly) should not provide false reassurance. Similarly, patients with metabolic syndrome components—particularly type 2 diabetes, which independently increases fibrosis risk—may benefit from more intensive monitoring even with borderline scores. Your healthcare team will consider your complete clinical picture, including age and comorbidities, when determining whether additional testing or specialist referral is appropriate.
Managing Non-Alcoholic Fatty Liver Disease and Fibrosis
Effective management of NAFLD and associated fibrosis centres on lifestyle modification and addressing underlying metabolic risk factors. Currently, no medications are licensed specifically to treat NAFLD in the UK, making lifestyle intervention the cornerstone of therapy across all fibrosis stages.
Weight loss remains the most evidence-based intervention for NAFLD. Studies demonstrate that losing 7–10% of body weight can significantly reduce liver fat content, inflammation, and even fibrosis in some patients. This should be achieved through a combination of dietary modification and increased physical activity. The Mediterranean diet pattern—rich in vegetables, fruits, whole grains, legumes, nuts, and olive oil—has shown particular benefit for liver health. Reducing intake of refined carbohydrates, added sugars (especially fructose-containing beverages), and saturated fats is equally important. Aim for at least 150 minutes of moderate-intensity aerobic exercise weekly, as recommended by the UK Chief Medical Officers' physical activity guidelines, with resistance training twice weekly to improve insulin sensitivity.
Optimising metabolic comorbidities is essential for preventing fibrosis progression. If you have type 2 diabetes, achieving good glycaemic control reduces liver inflammation. Target HbA1c levels should be individualised in discussion with your healthcare team, as recommended by NICE NG28. Certain diabetes medications, particularly pioglitazone and GLP-1 receptor agonists, have shown promise in improving liver outcomes in clinical trials. However, these medications are not licensed for NAFLD treatment and should be considered only for their licensed diabetes indications, under specialist guidance, or as part of clinical trials. Cardiovascular risk management is equally critical, as cardiovascular disease represents the leading cause of mortality in NAFLD patients. This includes managing hypertension, dyslipidaemia (statins are safe in NAFLD and should not be withheld), and smoking cessation.
Alcohol consumption: If you drink alcohol, stay within the UK Chief Medical Officers' low-risk drinking guidelines of no more than 14 units per week, spread over 3 or more days. If you have advanced fibrosis or cirrhosis, your specialist may advise complete abstinence, as even modest alcohol intake may accelerate disease progression. Discuss your individual situation with your healthcare team.
Avoiding hepatotoxins protects your liver from additional injury. Review all medications and supplements with your GP, as some over-the-counter preparations and herbal remedies can cause liver injury. If you experience any suspected side effects from medications, report them via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.
Regular monitoring through your GP or specialist team allows early detection of disease progression. Patients with confirmed cirrhosis or otherwise eligible high-risk groups require hepatocellular carcinoma (HCC) surveillance with ultrasound scans every 6 months, with or without alpha-fetoprotein (AFP) testing, as recommended by BSG and BASL guidance. Your specialist will advise whether you meet the criteria for surveillance. If you experience new symptoms such as unexplained weight loss, abdominal swelling, confusion, jaundice, or vomiting blood, contact your GP promptly or attend A&E, as these may indicate disease progression or complications requiring urgent assessment.
Frequently Asked Questions
How accurate is the NAFLD Fibrosis Score at detecting liver scarring?
The NAFLD Fibrosis Score has a negative predictive value exceeding 90% for low-risk scores, meaning it is highly reliable at ruling out advanced fibrosis in patients scoring below -1.455. However, positive predictive values for high-risk scores range from 60–80%, so additional testing or specialist assessment is typically needed to confirm the presence of advanced scarring.
Can I use the NAFLD Fibrosis Score if I'm over 65 years old?
The standard NAFLD Fibrosis Score cut-offs may overestimate fibrosis risk in patients aged 65 years or older because age is a component of the calculation. Your healthcare team may use age-adjusted thresholds or recommend alternative testing strategies, such as the Enhanced Liver Fibrosis (ELF) test or transient elastography, to ensure accurate assessment in older adults.
What happens if my NAFLD Fibrosis Score falls in the intermediate range?
An intermediate score (-1.455 to 0.676) indicates uncertainty about your fibrosis status and requires further non-invasive testing to clarify your risk. In line with NICE guidance, your GP or specialist will typically arrange an Enhanced Liver Fibrosis (ELF) test or transient elastography (FibroScan) to provide additional information and guide your ongoing management.
Is the NAFLD Fibrosis Score the same as the FIB-4 index?
No, the NAFLD Fibrosis Score and FIB-4 index are different non-invasive scoring systems, though both assess fibrosis risk in NAFLD using routine blood tests and clinical data. The NAFLD Fibrosis Score uses six parameters (including BMI, diabetes status, and albumin), whilst FIB-4 uses four (age, AST, ALT, and platelet count), making it simpler but potentially less discriminatory in certain populations.
Will losing weight improve my NAFLD Fibrosis Score?
Yes, weight loss can improve the underlying liver disease and potentially your NAFLD Fibrosis Score over time, as losing 7–10% of body weight has been shown to reduce liver fat, inflammation, and even fibrosis in some patients. However, the score itself is a snapshot assessment, so your healthcare team will use repeat testing after lifestyle changes to monitor disease progression or improvement.
Do I need a liver biopsy if my NAFLD Fibrosis Score is high?
Not necessarily—a high NAFLD Fibrosis Score (>0.676) indicates you should be referred to specialist hepatology services for comprehensive assessment, which may include additional non-invasive tests such as transient elastography or the ELF test. Liver biopsy is reserved for cases where non-invasive tests give conflicting results, where there is diagnostic uncertainty, or when considering participation in clinical trials, as it carries procedural risks.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
